The companyâ€™s disclosures describe a multifaceted approach to sustaining operations and adapting to external pressures, including a corporate compliance program that actively identifies, prevents and mitigates risk while fostering a culture of compliance; a process of closely monitoring discovery, clinical trials and nonclinical study results and frequently evaluating development programs in light of new data and scientific, business and commercial insights with the objective of balancing risk and potential and permitting abrupt changes in focus and priorities; substantial and consistent investment in internal research activities and strategic collaborations to diversify the risks inherent in drug development, maintain business continuity through service innovation and allocate resources across multiple therapeutic areas; dedicated efforts to obtain and maintain appropriate levels of reimbursement from third-party payors in diverse markets to preserve financial resources and operational flexibility; use of a revolving credit facility and periodic equity issuances under employee benefit plans to support liquidity under nominal and extreme conditions; ongoing reassessment and adjustment of estimates for net product revenues, inventory recoverability and contingent payments based on evolving information; and the structuring and deconsolidation of variable interest entities to enable the organization to reconfigure its commitments, leverage external knowledge and reconstitute its strategic trajectory toward future resilience amid regulatory, commercial and environmental perturbations.